This inventor holds 1 USPTO granted patent. Top assignee: Jiangnan University. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Yuanyuan Mi: Innovator in Cancer Treatment
Introduction
Yuanyuan Mi is a prominent inventor based in Wuxi, China. She has made significant contributions to the field of biological medicine, particularly in the treatment of castration-resistant prostate cancer (CRPC). Her innovative approach combines existing drugs with new strategies to enhance treatment efficacy.
Latest Patents
Yuanyuan Mi holds a patent for the "Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer." This patent discloses the use of polaprezinc (Pola) in developing a drug that targets CRPC. The invention represents a novel strategy by combining Pola with an androgen receptor antagonist for the first time. This combination has shown remarkable improvements in the effectiveness of enzalutamide, a drug used to inhibit CRPC. The research conducted provides multi-angle and multi-level verification, highlighting the clinical significance of this new drug composition.
Career Highlights
Yuanyuan Mi is affiliated with Jiangnan University, where she continues her research and development in the field of cancer treatment. Her work has not only contributed to scientific knowledge but also holds the potential for significant clinical applications.
Collaborations
Yuanyuan Mi collaborates with esteemed colleagues, including Rong Wang and Yongquan Chen, to further advance her research initiatives. Their combined expertise enhances the quality and impact of their work in the medical field.
Conclusion
Yuanyuan Mi's innovative contributions to cancer treatment exemplify the importance of combining existing therapies with new strategies. Her work has the potential to transform the landscape of CRPC treatment and improve patient outcomes.